Trial reportMolecular oncology2017
miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo.
Trial report in Molecular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Intelligent structure prediction and visualization analysis of non-coding RNA in osteosarcoma research.Frontiers in oncology · 2024Pooled it
- Epigenetic modification of cuproptosis by non-coding RNAs in cancer drug resistance.Molecular cancer · 2025Review
- A 10-year bibliometric analysis in the field of osteosarcoma treatment from 2014 to 2023.Discover oncology · 2025Article
- A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics.medRxiv : the preprint server for health sciences · 2024Article
- MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.Frontiers in pharmacology · 2024Review
- The role of polyphenols in overcoming cancer drug resistance: a comprehensive review.Cellular & molecular biology letters · 2022Review
- An overview of resistance to chemotherapy in osteosarcoma and future perspectives.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Individualized assessment of risk and overall survival in patients newly diagnosed with primary osseous spinal neoplasms with synchronous distant metastasis.Frontiers in public health · 2022Article
- Exosomal MiRNAs in Osteosarcoma: Biogenesis and Biological Functions.Frontiers in pharmacology · 2022Review
- Enrichment of Wee1/CDC2 and NF-κB Signaling Pathway Constituents Mutually Contributes to CDDP Resistance in Human Osteosarcoma.Cancer research and treatment · 2022Article
- Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/Akt axis.Journal of experimental & clinical cancer research : CR · 2021Article
- Construction of five microRNAs prognostic markers and a prognostic model for clear cell renal cell carcinoma.Translational cancer research · 2021Article
- Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo.Frontiers in pharmacology · 2021Article
- miR-26a Reverses Multidrug Resistance in Osteosarcoma by Targeting MCL1.Frontiers in cell and developmental biology · 2021Article
- Carcinoma-associated fibroblasts promote the proliferation and metastasis of osteosarcoma by transferring exosomal LncRNA SNHG17.American journal of translational research · 2021Article
- Role of microRNAs in the crosstalk between osteosarcoma cells and the tumour microenvironment.Journal of bone oncology · 2020Review
- MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.Molecular medicine reports · 2020Article
- Influence mechanism of miRNA-144 on proliferation and apoptosis of osteosarcoma cells.Oncology letters · 2020Article
- miR-221-3p and miR-15b-5p promote cell proliferation and invasion by targeting Axin2 in liver cancer.Oncology letters · 2019Article
- miRNA signatures in childhood sarcomas and their clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The development of multidrug resistance (MDR) in cancer cells to chemotherapy drugs continues to be a major clinical problem. MicroRNAs (miRNA, miR) play an important role in regulating tumour cell growth and survival; however, the role of miRs in the development of drug resistance in osteosarcoma cells is largely uncharacterized. We sought to identify and characterize human miRs that act as key regulators of MDR in osteosarcoma. We utilized a miR microarray to screen for differentially expressed miRs in osteosarcoma MDR cell lines. We determined the mechanisms of the deregulation of expression of miR-15b in osteosarcoma MDR cell lines, and its association with clinically obtained tumour samples was examined in tissue microarray (TMA). The significance of miR-15b in reversing drug resistance was evaluated in a mouse xenograft model of MDR osteosarcoma. We identified miR-15b as being significantly (P < 0.01) downregulated in KHOS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.